23andMe Considers Sale

23andMe weighing up sale of the company as cash runs dry
A pioneer in genetic heritage services, 23andMe has seen much of its share price wiped out in the past year as it struggles to find a sustainable business model. Once occupying a value of $6bn, the company diversified beyond DNA testing and started a drug research business along with more specific diagnostic insights for customers.
23andMe Considers Sale as Cash Runs Low
The DNA-testing company is exploring its options, including a business combination and the sale of some or all of its assets.
23andMe weighs a sale as cash dwin­dles
Em­bat­tled ge­net­ics test­ing gi­ant 23andMe is think­ing of sell­ing it­self as it runs out of cash. The com­pa­ny needs to raise more mon­ey to con­tin­ue …
23andMe says it's exploring alternatives, including a sale
Genetic testing firm 23andMe (NASDAQ:ME) said it formed a special board committee to review strategic alternatives. The special committee will look at options including a sale, business combination, licensing of assets,
23andMe announces exploration of strategic alternatives
The Special Committee of the board of 23andMe Holding Co. announced that it has undertaken a process to explore strategic alternatives, including, among other alternatives, a poss
23andMe is exploring strategic alternatives, looking to raise capital
Anne Wojcicki, co-founder and chief executive officer of 23andme Inc., during the South by Southwest (SXSW) festival in Austin, Texas, US, on Friday, March 10, 2023. 23andMe said it's started exploring strategic alternatives,
Genetic test maker 23andMe eyes strategic alternatives, including a sale
Genetic testing pioneer 23andMe is looking at strategic alternatives, including a possible sale, it said Tuesday, months ...
23andMe Board Explores Strategic Alternatives Amid Restructuring
23andMe Holding Co. ( ME, Financials) announced that its board's Special Committee is reviewing strategic alternatives, ...
23andMe has been quietly exploring a possible sale of its telehealth business, Lemonaid
The struggling genetic-testing 23andMe is looking for a buyer for the virtual-care business it acquired in 2021, Business ...
Nature6d
What went wrong at 23andMe? Why the genetic-data giant risks collapse
At-home DNA testing is no longer in high demand — and critics have raised concerns about unreliable tests and privacy.
Stocks to Watch: 23andMe, Manhattan Associates, Nextracker
Manhattan Associates' 2025 outlook missed estimates. The provider of supply-chain and omnichannel-commerce solutions said it expects adjusted per-share earnings of $4.45 to $4.55 on revenue of $1.06 ...
23andMe Reports Third Quarter Fiscal Year 2025 Financial Results
Company Notes Continued Concerns Regarding Liquidity and Consideration of Potential Ways to Address Operational and Financial ...